Business
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ STOCKHOLM: HNSA) and SERB S.A. ("SERB") today announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.
About this update from Hansa Biopharma Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"The agreement covers the European Union, United Kingdom, Switzerland, Norway, Liechtenstein, Iceland and the MENA region","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Significantly enhances Hansa's financial position, ensuring a robust U.S. launch and provides path to profitability, subject to US approval","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization ","length":133,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":396,"olType":false},{"type":"text","content":"LUND, Sweden, May 19, 2026 /PRNewswire/ -- Hansa Biopharma AB ("Hansa" or "the Company") (NASDAQ STOCKHOLM: HNSA) and SERB S.A. ("SERB") today announced an exclusive licensing agreement for development and commercialization of IDEFIRIX (imlifidase) in the European Union (EU), United Kingdom (UK), Switzerland, Norway, Liechtenstein, Iceland and MENA (Middle East and North Africa) regions.","length":420,"tagName":"p"},{"type":"text","content":"IDEFIRIX is a first-in-class treatment that specifically targets and cleaves all classes of immunoglobulin G (IgG) antibodies within 2 to 6 hours. It is conditionally authorized by the European Commission for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch test against an available deceased donor. IDEFIRIX offers a pioneering breakthrough for patients with a significant unmet medical need.","length":455,"tagName":"p"},{"type":"text","content":"Renée Aguiar-Lucander, CEO of Hansa Biopharma, said "This agreement is transformative for Hansa Biopharma. It allows patients in the region to benefit from a partner with an established commercial footprint and proven growth track record in Europe. At the same time, it crystallizes the value of the franchise and significantly strengthens our financial position assuring an optimized US launch and a pathway to profitability, subject to a 2026 US approval, as well as the continued pursuit of our R&D pipeline." ","length":526,"tagName":"p"},{"type":"text","content":"Jeremie Urbain, Chairman of SERB, said "SERB is committed to expanding access to transplantation for highly sen...